MedTrace Logo

A Performance Analysis of the Peritoneal Ultrafiltration (PUF) Achieved With the Carry Life® UF

NCT03724682 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-08-28

No results posted yet for this study

Summary

The Carry Life UF device performs peritoneal ultrafiltration by adding a concentrated glucose to peritoneal dialysis fluid which has been instilled into the abdomen prior to the connection of the device. Maintaining the glucose concentration in the intraperitoneal fluid results in an increased fluid removal (ultrafiltration).

The clinical investigation will evaluate the ultrafiltration achieved with the Carry Life UF device compared to standard peritoneal dialysis (PD) therapy

Conditions

  • Chronic Renal Failure

Interventions

DEVICE

Carry Life UF device

Treatment with the Carry Life UF device compared to standard PD therapy

Sponsors & Collaborators

  • Triomed AB

    lead INDUSTRY

Principal Investigators

  • Ann-Cathrine Johansson · Renal Unit, Skånes Universitetssjukhus, Malmö

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2019-06-26
Completion
2019-06-26

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724682 on ClinicalTrials.gov